CL2018003707A1 - Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo. - Google Patents
Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo.Info
- Publication number
- CL2018003707A1 CL2018003707A1 CL2018003707A CL2018003707A CL2018003707A1 CL 2018003707 A1 CL2018003707 A1 CL 2018003707A1 CL 2018003707 A CL2018003707 A CL 2018003707A CL 2018003707 A CL2018003707 A CL 2018003707A CL 2018003707 A1 CL2018003707 A1 CL 2018003707A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- vortioxetine
- plasma
- administration
- dosing regimens
- Prior art date
Links
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002263 vortioxetine Drugs 0.000 title abstract 2
- 230000001430 anti-depressive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001932 seasonal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
UN RÉGIMEN DE DOSIFICACIÓN QUE COMPRENDE LA ADMINISTRACIÓN SIMULTÁNEA DE DOS COMPOSICIONES FARMACÉUTICAS, EN DONDE LA PRIMERA COMPOSICIÓN FARMACÉUTICA ES UNA COMPOSICIÓN QUE COMPRENDE VORTIOXETINA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA PARA UNA ADMINISTRACIÓN ORAL UNA VEZ AL DÍA, Y LA SEGUNDA COMPOSICIÓN FARMACÉUTICA ES UNA COMPOSICIÓN QUE COMPRENDE VORTIOXETINA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA QUE, JUNTO CON DICHA PRIMERA COMPOSICIÓN, LOGRA RÁPIDAMENTE UN NIVEL EN PLASMA DE ESTADO ESTACIONARIO DE VORTIOXETINA EN DICHO PACIENTE, NIVEL EN PLASMA DE ESTADO ESTACIONARIO QUE ES ESENCIALMENTE EL MISMO QUE EL NIVEL EN PLASMA DE ESTADO ESTACIONARIO DE VORTIOXETINA LOGRADO POR LA ADMINISTRACIÓN A DICHO PACIENTE DE DICHA PRIMERA COMPOSICIÓN SOLA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357722P | 2016-07-01 | 2016-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003707A1 true CL2018003707A1 (es) | 2019-02-15 |
Family
ID=59239917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003707A CL2018003707A1 (es) | 2016-07-01 | 2018-12-20 | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo. |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9820984B1 (es) |
| EP (1) | EP3478289A1 (es) |
| JP (1) | JP2019524682A (es) |
| KR (1) | KR20190025556A (es) |
| CN (1) | CN109310691A (es) |
| AU (1) | AU2017288456A1 (es) |
| BR (1) | BR112018003930A2 (es) |
| CA (1) | CA3026728A1 (es) |
| CL (1) | CL2018003707A1 (es) |
| CO (1) | CO2018013792A2 (es) |
| IL (1) | IL263584A (es) |
| MA (1) | MA45532A (es) |
| MX (1) | MX2018015759A (es) |
| RU (1) | RU2018144248A (es) |
| SG (1) | SG11201810644TA (es) |
| TW (1) | TW201806599A (es) |
| WO (1) | WO2018002115A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018015759A (es) * | 2016-07-01 | 2019-03-21 | H Lundbeck As | Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo. |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| AU2007260355B2 (en) | 2006-06-16 | 2013-08-15 | H. Lundbeck A/S | 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
| HRP20110412T1 (hr) | 2006-06-16 | 2011-06-30 | H. Lundbeck A/S | Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TWI432194B (zh) | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途 |
| TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| TW201033181A (en) | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
| RS53539B1 (sr) | 2009-04-24 | 2015-02-27 | H. Lundbeck A/S | Tečne formulacije soli 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina |
| EA021321B1 (ru) | 2009-08-24 | 2015-05-29 | Х. Лундбекк А/С | Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина |
| TW201212918A (en) | 2010-08-23 | 2012-04-01 | Lundbeck & Co As H | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
| EP2800746B1 (en) | 2012-01-03 | 2019-04-17 | H. Lundbeck A/S | Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine |
| EA028300B1 (ru) | 2012-12-13 | 2017-10-31 | Х. Лундбекк А/С | Композиции, содержащие вортиоксетин и донепезил |
| MX362355B (es) | 2013-02-22 | 2019-01-14 | H Lundbeck As | Proceso de fabricacion de vortioxetina. |
| MX368870B (es) * | 2013-12-20 | 2019-10-21 | H Lundbeck As | Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas. |
| JO3456B1 (ar) | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| MX2018015759A (es) * | 2016-07-01 | 2019-03-21 | H Lundbeck As | Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo. |
-
2017
- 2017-06-28 MX MX2018015759A patent/MX2018015759A/es unknown
- 2017-06-28 WO PCT/EP2017/065958 patent/WO2018002115A1/en not_active Ceased
- 2017-06-28 CA CA3026728A patent/CA3026728A1/en not_active Abandoned
- 2017-06-28 MA MA045532A patent/MA45532A/fr unknown
- 2017-06-28 US US15/636,238 patent/US9820984B1/en not_active Expired - Fee Related
- 2017-06-28 CN CN201780033672.4A patent/CN109310691A/zh active Pending
- 2017-06-28 BR BR112018003930A patent/BR112018003930A2/pt not_active Application Discontinuation
- 2017-06-28 AU AU2017288456A patent/AU2017288456A1/en not_active Abandoned
- 2017-06-28 JP JP2018568721A patent/JP2019524682A/ja active Pending
- 2017-06-28 RU RU2018144248A patent/RU2018144248A/ru not_active Application Discontinuation
- 2017-06-28 EP EP17733829.0A patent/EP3478289A1/en not_active Withdrawn
- 2017-06-28 SG SG11201810644TA patent/SG11201810644TA/en unknown
- 2017-06-28 TW TW106121573A patent/TW201806599A/zh unknown
- 2017-06-28 KR KR1020187036532A patent/KR20190025556A/ko not_active Withdrawn
- 2017-09-13 US US15/703,572 patent/US9913839B2/en not_active Expired - Fee Related
-
2018
- 2018-02-06 US US15/890,006 patent/US10258617B2/en not_active Expired - Fee Related
- 2018-12-09 IL IL263584A patent/IL263584A/en unknown
- 2018-12-19 CO CONC2018/0013792A patent/CO2018013792A2/es unknown
- 2018-12-20 CL CL2018003707A patent/CL2018003707A1/es unknown
-
2019
- 2019-03-04 US US16/291,865 patent/US20200030319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019524682A (ja) | 2019-09-05 |
| CO2018013792A2 (es) | 2019-01-18 |
| AU2017288456A1 (en) | 2018-12-13 |
| WO2018002115A1 (en) | 2018-01-04 |
| SG11201810644TA (en) | 2018-12-28 |
| EP3478289A1 (en) | 2019-05-08 |
| MA45532A (fr) | 2019-05-08 |
| RU2018144248A (ru) | 2020-08-03 |
| US20200030319A1 (en) | 2020-01-30 |
| US10258617B2 (en) | 2019-04-16 |
| TW201806599A (zh) | 2018-03-01 |
| CN109310691A (zh) | 2019-02-05 |
| BR112018003930A2 (pt) | 2018-09-25 |
| KR20190025556A (ko) | 2019-03-11 |
| US20180000815A1 (en) | 2018-01-04 |
| US9913839B2 (en) | 2018-03-13 |
| CA3026728A1 (en) | 2018-01-04 |
| US9820984B1 (en) | 2017-11-21 |
| MX2018015759A (es) | 2019-03-21 |
| US20180153881A1 (en) | 2018-06-07 |
| IL263584A (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003542A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CO2017002682A2 (es) | Composiciones y métodos para recubrimientos cannabinoides para uso en la entrega de fármacos | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| RU2016131454A (ru) | Применения витамина d и его композиций для антибиоза | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| CL2018003707A1 (es) | Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo. | |
| MX2017012459A (es) | Formulacion de complejo farmaceutico que comprende amlodipina, losartan y clortalidona. | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX2018000872A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| CL2017000026A1 (es) | Formas de dosificación farmacéutica | |
| CL2022000095A1 (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
| MX2020004403A (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| CO2019013645A2 (es) | Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas | |
| AR105087A1 (es) | Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona | |
| CO2020006701A2 (es) | Composiciones farmacéuticas orales de lorazepam resistentes al alcohol | |
| GT201500333A (es) | Composición farmacéutica sinergística de dos analgésicos con distinto perfil famacocinético | |
| CL2018001236A1 (es) | Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo. | |
| AR104972A1 (es) | COMPOSICIONES DE HIDROXIPROPIL b-CICLODEXTRINA Y MÉTODOS |